- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04417946
Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)
October 19, 2023 updated by: Yale University
The aim of this study is to examine the effect of social media intervention on the use of pre-exposure prophylaxis (PrEP) by young men who have sex with men (YMSM) in the greater New Haven area.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
There are three specific aims of this study.
In the first specific aim, two focus group discussions (FGDs) of YMSM will be conducted to assess the feasibility and acceptability of social media intervention.
In the second specific aim of the study, a quasi-pre-post experimental study will be conducted to examine the effect of social media intervention on PrEP uptake (primary outcome) and PrEP use intention, HIV testing, PrEP knowledge, self-efficacy and social support (secondary outcome).
In the third specific aim of the study, the most important topics around PrEP will be assessed on the Facebook page of the intervention group by conducting a content analysis.
Study Type
Interventional
Enrollment (Actual)
227
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University
-
New Haven, Connecticut, United States, 06510
- APNH: A Place to Nourish your Health (APNH)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 29 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Biologically male or transgender man
- Self-identification as gay or bi-sexual
- Resident of greater New Haven area
- Willing and able to use Facebook during the span of the study
Exclusion Criteria:
• Women will not be included in the study
- Under the age of 18 and over the age of 29
- Unable to provide informed consent
- Verbally or physically threatening to research staff
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PrEP Messages
The peer leaders and the study staff will post PrEP related health messages
|
The peer leaders and the study staff will post PrEP related health messages
|
Active Comparator: Health messages
The peer leaders and study staff will post general health messages that are not related to sexual health.
|
The peer leaders and study staff will post general health messages that are not related to sexual health
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP uptake
Time Frame: PrEP uptake at baseline
|
Actual PrEP uptake: participants self report if they use prep (Yes/No)
|
PrEP uptake at baseline
|
PrEP uptake
Time Frame: PrEP uptake (Yes/No) at 24-weeks
|
Actual PrEP uptake: participants self report if they use prep (Yes/No)
|
PrEP uptake (Yes/No) at 24-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV testing
Time Frame: baseline
|
Date of the last HIV test: participants self report the date of their last HIV test as a function of time in days.
|
baseline
|
HIV testing
Time Frame: 24-weeks
|
Date of the last HIV test: participants self report the date of their last HIV test as a function of time in days.
|
24-weeks
|
PrEP use intention
Time Frame: PrEP use intention at baseline
|
Willingness to use/likelihood of using PrEP in the next 6 months : self reported assessment to measure participants' willingness to use prep in the next 6 month s on a single question using Likert scale from 1(very unlikely) to 7 (very likely)
|
PrEP use intention at baseline
|
PrEP use intention
Time Frame: PrEP use intention at 24-weeks
|
Willingness to use/likelihood of using PrEP in the next 6 months : self reported assessment to measure participants' willingness to use prep in the next 6 month s on a single question using Likert scale from 1(very unlikely) to 7 (very likely)
|
PrEP use intention at 24-weeks
|
PrEP knowledge
Time Frame: PrEP knowledge at baseline
|
Knowledge of PrEP for HIV prevention: self reported assessment to measure participants' knowledge on PrEP on a set of True or False questions
|
PrEP knowledge at baseline
|
PrEP knowledge
Time Frame: PrEP knowledge at 24-weeks
|
Knowledge of PrEP for HIV prevention: self reported assessment to measure participants' knowledge on PrEP on a set of True or False questions
|
PrEP knowledge at 24-weeks
|
self efficacy to use PrEP
Time Frame: self efficacy to use PrEP at baseline
|
Beliefs in his/her ability of using PrEP: participants self report their level of confidence in taking PrEP on a set of items using Likert scales from 1 (Not at all confident) to 5 (completely confident)
|
self efficacy to use PrEP at baseline
|
self efficacy to use PrEP
Time Frame: self efficacy to use PrEP at 24-weeks
|
Beliefs in his/her ability of using PrEP: participants self report their level of confidence in taking PrEP on a set of items using Likert scales from 1 (Not at all confident) to 5 (completely confident)
|
self efficacy to use PrEP at 24-weeks
|
motivation to use PrEP
Time Frame: motivation to use PrEP at baseline
|
How motivated s/he is to use PrEP and what motivates s/he to use PrEP: self reported assessment to measure participants' different types of motivation to use PrEP on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
motivation to use PrEP at baseline
|
motivation to use PrEP
Time Frame: motivation to use PrEP at 24-weeks
|
How motivated s/he is to use PrEP and what motivates s/he to use PrEP: self reported assessment to measure participants' different types of motivation to use PrEP on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
motivation to use PrEP at 24-weeks
|
PrEP stigma
Time Frame: PrEP stigma at baseline
|
Perceived stigma related to PrEP use: self reported assessment to measure perception of stigma related to PrEP use on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
PrEP stigma at baseline
|
PrEP stigma
Time Frame: PrEP stigma at 24-weeks
|
Perceived stigma related to PrEP use: self reported assessment to measure perception of stigma related to PrEP use on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
PrEP stigma at 24-weeks
|
Social support for PrEP use
Time Frame: Social support for PrEP use at baseline
|
Help and support that individuals receive that can facilitate PrEP uptake: Perceived stigma related to PrEP use: self reported assessment to measure perception of social support related to PrEP use on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
Social support for PrEP use at baseline
|
Social support for PrEP use
Time Frame: Social support for PrEP use at 24-weeks
|
Help and support that individuals receive that can facilitate PrEP uptake: Perceived stigma related to PrEP use: self reported assessment to measure perception of social support related to PrEP use on a set of items using Likert scales from 1(strongly disagree) to 7 (strongly agree)
|
Social support for PrEP use at 24-weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Frederick Altice, M.D., M.A., Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2018
Primary Completion (Actual)
April 1, 2023
Study Completion (Actual)
April 1, 2023
Study Registration Dates
First Submitted
June 2, 2020
First Submitted That Met QC Criteria
June 2, 2020
First Posted (Actual)
June 5, 2020
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 19, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2000022728
- 1H79TI080736 (Other Grant/Funding Number: Substance Abuse and Mental Health Services Administration)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
All data will be kept confidential.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on PrEP messages
-
Johns Hopkins Bloomberg School of Public HealthRecruiting
-
Yale UniversityGilead SciencesNot yet recruitingHIV Prevention | PrEP Uptake | PrEP AwarenessUnited States
-
University of UlsterNorthern Ireland Chest Heart and StrokeCompleted
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Penn State UniversityRecruiting
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Kenyatta National...Completed
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Hennepin Healthcare Research InstituteCompleted
-
Hilary L Surratt, PhDNational Institute on Drug Abuse (NIDA)Active, not recruitingHIV PreventionUnited States
-
Montefiore Medical CenterNew York State Psychiatric InstituteActive, not recruiting
-
University of California, San FranciscoNational Institute of Nursing Research (NINR); San Francisco Department of...CompletedHIV/AIDSUnited States